Intec Pharma Ltd. (NASDAQ:NTEC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
NTEC has been the topic of several other research reports. CIBC reissued an “outperform” rating and issued a $15.00 price target (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Oppenheimer Holdings, Inc. upped their target price on shares of Intec Pharma from $10.00 to $15.00 and gave the stock an “outperform” rating in a report on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Intec Pharma currently has a consensus rating of “Buy” and a consensus target price of $12.25.
ILLEGAL ACTIVITY WARNING: “Intec Pharma Ltd. (NTEC) Rating Increased to Hold at Zacks Investment Research” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thestockobserver.com/2017/10/13/intec-pharma-ltd-ntec-rating-increased-to-hold-at-zacks-investment-research.html.
A hedge fund recently raised its stake in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 522,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. owned approximately 3.80% of Intec Pharma worth $2,977,000 as of its most recent SEC filing. 16.41% of the stock is owned by hedge funds and other institutional investors.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.